Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables (2020 - 2024)

Historic Receivables for Janux Therapeutics (JANX) over the last 5 years, with Q2 2024 value amounting to $12.1 million.

  • Janux Therapeutics' Receivables changed N/A to $12.1 million in Q2 2024 from the same period last year, while for Jun 2024 it was $12.1 million, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Janux Therapeutics reported Receivables of $12.1 million as of Q2 2024.
  • Over the past 5 years, Janux Therapeutics' Receivables peaked at $12.1 million during Q2 2024, and registered a low of $400000.0 during Q2 2021.
  • Its 5-year average for Receivables is $4.0 million, with a median of $2.2 million in 2023.
  • Examining YoY changes over the last 5 years, Janux Therapeutics' Receivables showed a top increase of 45062.5% in 2024 and a maximum decrease of 45062.5% in 2024.
  • Janux Therapeutics' Receivables (Quarter) stood at $8.0 million in 2020, then crashed by 95.0% to $400000.0 in 2021, then increased by 25.0% to $500000.0 in 2022, then skyrocketed by 332.2% to $2.2 million in 2023, then skyrocketed by 457.89% to $12.1 million in 2024.
  • Its last three reported values are $12.1 million in Q2 2024, $4.4 million for Q1 2024, and $2.2 million during Q4 2023.